MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Becton, Dickinson and Company Gross Profit 2011-2026 | BDX
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 8.29 B | 7.26 B | 5.94 B | 5.99 B | 4.7 B | 4.3 B | 4.17 B | 3.95 B | 4.09 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.29 B | 3.95 B | 5.41 B |
Quarterly Gross Profit Becton, Dickinson and Company
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.21 B | 1.66 B | 1.73 B | 1.98 B | 2.27 B | 2.07 B | 1.97 B | 1.97 B | 2.09 B | 2.02 B | 1.61 B | 1.55 B | 1.55 B | 1.5 B | 1.43 B | 1.45 B | 1.55 B | 1.55 B | 1.48 B | 1.41 B | 1.43 B | 1.17 B | 1.05 B | 1.04 B | 1.1 B | 1.11 B | 1.05 B | 1.04 B | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.27 B | 1.04 B | 1.57 B |
Gross Profit of other stocks in the Medical instruments industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
62.4 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
959 M | $ 19.94 | 1.45 % | $ 10.2 B | USA |
 |
Luminex Corporation
LMNX
|
248 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
479 K | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
86.5 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
436 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
1.68 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.48 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
1.38 B | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
9.51 M | $ 8.05 | -2.07 % | $ 162 M | USA |
 |
Alcon
ALC
|
5.51 B | $ 80.14 | 1.44 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
348 M | $ 37.41 | 2.77 % | $ 1.76 B | USA |
 |
electroCore
ECOR
|
13.2 M | $ 6.53 | 3.82 % | $ 36 K | USA |
 |
ICU Medical
ICUI
|
825 M | $ 148.7 | 0.28 % | $ 3.63 B | USA |
 |
AngioDynamics
ANGO
|
158 M | $ 10.21 | 1.37 % | $ 417 M | USA |
 |
InfuSystem Holdings
INFU
|
62.6 M | $ 8.74 | 2.7 % | $ 180 M | USA |
 |
The Cooper Companies
COO
|
2.68 B | $ 81.74 | 0.05 % | $ 16.3 B | USA |
 |
Haemonetics Corporation
HAE
|
749 M | $ 76.43 | -3.0 % | $ 3.85 B | USA |
 |
Harvard Bioscience
HBIO
|
66.1 M | $ 0.57 | -2.96 % | $ 24.2 M | USA |
 |
Glaukos Corporation
GKOS
|
239 M | $ 103.94 | -5.75 % | $ 5.03 B | USA |
 |
Repro Med Systems
KRMD
|
16.7 M | $ 5.56 | -3.81 % | $ 254 M | USA |
 |
Isoray
ISR
|
817 K | - | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
408 M | $ 163.14 | 4.95 % | $ 5.09 B | USA |
 |
LeMaitre Vascular
LMAT
|
151 M | $ 85.13 | 2.15 % | $ 1.91 B | USA |
 |
Masimo Corporation
MASI
|
1 B | $ 137.72 | 6.07 % | $ 7.34 B | USA |
 |
Merit Medical Systems
MMSI
|
643 M | $ 81.8 | 0.89 % | $ 4.76 B | USA |
 |
Intuitive Surgical
ISRG
|
5.63 B | $ 547.88 | -2.48 % | $ 195 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.16 | 1.89 % | $ 22 M |  Israel |
 |
Nephros
NEPH
|
8.4 M | $ 4.4 | -0.51 % | $ 45.7 M | USA |
 |
Milestone Scientific
MLSS
|
6.43 M | $ 0.29 | 0.99 % | $ 23.1 M | USA |
 |
NeuroMetrix
NURO
|
1.68 M | - | 5.05 % | $ 9.02 M | USA |
 |
OraSure Technologies
OSUR
|
79.4 M | $ 2.69 | 3.27 % | $ 200 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.37 B | $ 24.14 | 3.92 % | $ 4.16 B | USA |
 |
Pro-Dex
PDEX
|
19.5 M | $ 40.05 | -0.72 % | $ 132 M | USA |
 |
Predictive Oncology
POAI
|
798 K | $ 7.28 | 1.0 % | $ 39.7 M | USA |
 |
Repligen Corporation
RGEN
|
151 M | $ 161.81 | -3.29 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
2.02 B | $ 259.06 | 1.71 % | $ 37.8 B | USA |
 |
STERIS plc
STE
|
2.4 B | $ 264.04 | 1.58 % | $ 26 B | USA |
 |
BioLife Solutions
BLFS
|
18.6 M | $ 24.28 | 1.59 % | $ 1.12 B | USA |
 |
Stereotaxis
STXS
|
14.9 M | $ 2.76 | 2.8 % | $ 223 M | USA |
 |
Retractable Technologies
RVP
|
-1.03 M | $ 0.72 | -2.7 % | $ 21.6 M | USA |
 |
STAAR Surgical Company
STAA
|
240 M | $ 21.52 | 1.82 % | $ 1.06 B | USA |
 |
Utah Medical Products
UTMD
|
7.1 M | $ 58.97 | 0.7 % | $ 214 M | USA |
 |
Teleflex Incorporated
TFX
|
1.7 B | $ 103.33 | -0.54 % | $ 4.84 B | USA |
 |
West Pharmaceutical Services
WST
|
998 M | $ 276.83 | 1.84 % | $ 20.2 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.96 B | $ 12.38 | 2.08 % | $ 2.52 B | USA |